Filtered By:
Drug: Celebrex

This page shows you your search results in order of relevance.

Order by Relevance | Date

Total 37 results found since Jan 2013.

FDA strengthens warning that NSAIDs increase heart attack and stroke risk
Back in 2005, the FDA warned that taking nonsteroidal anti-inflammatory drugs (NSAIDs) like ibuprofen and naproxen increased the risk of having a heart attack or stroke. Last week it took the unusual step of further strengthening this warning. This was done on the advice of an expert panel that reviewed new information about NSAIDs and their risks. Because NSAIDs are widely used, it’s important to be aware of downsides of taking an NSAID and to take steps to limit the risk. Many people take NSAIDs to relieve mild to moderate pain. These medications may be particularly effective in conditions in which pain results pri...
Source: New Harvard Health Information - July 13, 2015 Category: Consumer Health News Authors: Gregory Curfman, MD Tags: Heart Health heart attack heart disease NSAIDS Stroke Source Type: news

Celecoxib and Etoricoxib may reduce risk of ischemic stroke in patients with rheumatoid arthritis: A nationwide retrospective cohort study
ConclusionThis population-based retrospective cohort study has shown that Celecoxib and Etoricoxib reduce the risk of ischemic stroke in patients with RA in a dose- and time-dependent manner.
Source: Frontiers in Neurology - October 20, 2022 Category: Neurology Source Type: research

Ultra-Sensitive Molecular MRI of Vascular Cell Adhesion Molecule-1 Reveals a Dynamic Inflammatory Penumbra After Strokes Basic Sciences
Conclusions— MPIOs-αVCAM-1–enhanced imaging seems to be promising in the detection of individuals presenting with severe cerebrovascular responses after stroke, which could therefore benefit from anti-inflammatory treatments.
Source: Stroke - June 24, 2013 Category: Neurology Authors: Gauberti, M., Montagne, A., Marcos-Contreras, O. A., Le Behot, A., Maubert, E., Vivien, D. Tags: Computerized tomography and Magnetic Resonance Imaging, Thrombolysis, Endothelium/vascular type/nitric oxide Basic Sciences Source Type: research

Certain Painkillers Tied to Raised Risk of Death After Stroke
Celebrex and other COX-2 inhibitors should be prescribed with care, experts say Source: HealthDay Related MedlinePlus Pages: Pain Relievers, Stroke Rehabilitation
Source: MedlinePlus Health News - November 5, 2014 Category: Consumer Health News Source Type: news

Cardiovascular risk associated with celecoxib or etoricoxib: a meta-analysis of randomized controlled trials which adopted comparison with placebo or naproxen.
CONCLUSION: On the basis of our meta-analysis, we can state that symptomatic benefits induced by the prolonged administration of celecoxib may be partially invalidated by a concomitant increase in vascular risk, particularly the increased risk of myocardial infarction found in celecoxib-treated patients, compared to controls taking placebo. In contrast, treatment with etoricoxib proved not to result in an increased risk of serious vascular events when compared with both the placebo and naproxen. Our meta-analysis also denotes that the alternative to COXIBs, represented by naproxen, does not show significant benefit in term...
Source: Minerva Cardioangiologica - November 18, 2015 Category: Cardiology Tags: Minerva Cardioangiol Source Type: research

How To Avoid China ’ s Medicine Monopoly
I want to share a shocking statistic with you… Around 80% of all the pharmaceuticals sold in America — both prescription and over-the-counter — are manufactured in China. I’m talking about drugs for Parkinson’s and Alzheimer’s, blood pressure and blood thinners, diuretics, aspirin, antibiotics, and a big chunk of the world’s insulin and diabetes drugs — just to name a few.1 We don’t even make penicillin anymore. The last penicillin plant in the U.S. closed its doors in 2004. Americans who rely on medicine are now almost entirely at the mercy of a country whose relations with the U.S. have become more ...
Source: Al Sears, MD Natural Remedies - September 19, 2023 Category: Complementary Medicine Authors: Jacob Tags: Health Source Type: news

High-dose painkiller heart risk: small but significant
Conclusion This large review adds to, and expands on, the current evidence on the risks of vascular disease and gastrointestinal complications for different NSAIDs. It largely concentrates on trials of high doses of NSAIDs that can only be prescribed by a doctor. It is unclear from this study whether there is any risk from taking lower doses available over the counter. While most experts advise that low-dose NSAIDs, taken occasionally, are safe for most people, an accompanying editorial points out that there are still “large gaps” in evidence on the risks with lower doses of NSAIDs. While the risk to individuals is sma...
Source: NHS News Feed - May 30, 2013 Category: Consumer Health News Tags: Medication Heart/lungs Source Type: news

Non ‐steroidal anti‐inflammatory drug‐induced cardiovascular adverse events: a meta‐analysis
Summary What is known and objectiveAlthough non‐steroidal anti‐inflammatory drugs (NSAIDs) have been studied in randomized, controlled trials and meta‐analyses in an effort to determine their cardiovascular (CV) risks, no consensus has been reached. These studies continue to raise questions, including whether cyclooxygenase‐2 (COX‐2) selectivity plays a role in conferring CV risk. We performed a meta‐analysis of current literature to determine whether COX‐2 selectivity leads to an increased CV risk. MethodsWe utilized randomized, controlled trials and prospective cohort studies. We selected eight NSAIDs based...
Source: Journal of Clinical Pharmacy and Therapeutics - November 30, 2016 Category: Drugs & Pharmacology Authors: B. R. Gunter, K. A. Butler, R. L. Wallace, S. M. Smith, S. Harirforoosh Tags: Review Article Source Type: research

Godly gift for arthritis pain
Big Pharma is at it again… Creating and selling a drug that causes thousands of heart attacks and strokes each year. In 2015, the FDA asked drug makers to strengthen their warning labels. Since then, most have listed their dangerous side effects on the bottle. But one manufacturer thought they didn’t have to warn people about their dangerous drug. They marketed their product as a “unique” breakthrough. They even published studies promising it was “safe for long-term use.” 1 The drug is a 7-year-old arthritis drug called Actemra. It’s made by the Swiss pharmaceutical company Roche. ...
Source: Al Sears, MD Natural Remedies - October 5, 2017 Category: Complementary Medicine Authors: Al Sears Tags: Anti-Aging Source Type: news

Depression in the Context of Medical Disorders: New Pharmacological Pathways Revisited
In conclusion a hypothetic model for the implication of actual findings in everyday clinical practice is proposed. In this context personalized treatment could be used to tailor treatment to specific individuals according to their clinical endophenotypes. Moreover a potential target for the development of novel intervention strategies might be used.Neurosignals 2017;25:54 –73
Source: Neurosignals - October 17, 2017 Category: Neurology Source Type: research

Depression in the Context of Medical Disorders: New Pharmacological Pathways Revisited.
In conclusion a hypothetic model for the implication of actual findings in everyday clinical practice is proposed. In this context personalized treatment could be used to tailor treatment to specific individuals according to their clinical endophenotypes. Moreover a potential target for the development of novel intervention strategies might be used. PMID: 29041003 [PubMed - as supplied by publisher]
Source: Neuro-Signals - October 17, 2017 Category: Neurology Authors: Lang UE, Walter M Tags: Neurosignals Source Type: research

Depression in the Context of Medical Disorders: New Pharmacological Pathways Revisited
In conclusion a hypothetic model for the implication of actual findings in everyday clinical practice is proposed. In this context personalized treatment could be used to tailor treatment to specific individuals according to their clinical endophenotypes. Moreover a potential target for the development of novel intervention strategies might be used.Neurosignals 2017;25:54 –73
Source: Neurosignals - October 25, 2017 Category: Neurology Source Type: research

Comparative evaluation of cardiovascular outcomes in patients with osteoarthritis and rheumatoid arthritis on recommended doses of nonsteroidal anti-inflammatory drugs
Conclusion: From the analysis conducted, it appears that the risk for cardiovascular events in arthritis patients on licensed doses of NSAIDs varies considerably and is likely to depend on the individual compound.
Source: Therapeutic Advances in Musculoskeletal Disease - August 4, 2014 Category: Orthopaedics Authors: Fabule, J., Adebajo, A. Tags: Original Research Source Type: research

Influence of Experimental Subarachnoid Hemorrhage on Nicotine-induced Contraction of the Rat Basilar Artery in Relation to Arachidonic Acid Metabolites Signaling Pathway
Conclusions: One week after exposure to SAH, PLC, sPLA2, and COX-2 activity were enhanced and cPLA2 activity was inhibited. One hour after exposure to SAH, PLC activity was enhanced and cPLA2 and iPLA2 activity was inhibited. Such changes of inflammatory arachidonic acid metabolites by smoking after SAH may play important roles in fatal cerebral circulatory disorders, suggesting important implications for the etiology and pathogenesis of SAH.
Source: Journal of Stroke and Cerebrovascular Diseases - January 3, 2012 Category: Neurology Authors: Xu Ji, Aimin Wang, Cristina C. Trandafir, Kazuyoshi Kurahashi Tags: Original Articles Source Type: research

Some Pain Drugs Increase the Risk of Heart Attack
ROCHESTER, Minn. — Some of the most common pain drugs used by older adults who experience discomfort in muscles and joints can increase the risk of heart attack and stroke. The April issue of Mayo Clinic Health Letter covers the risks of nonsteroidal anti-inflammatory drugs (NSAIDs) that include celecoxib (Celebrex), diclofenac (Voltaren), ibuprofen (Advil, Motrin [...]
Source: Mayo Clinic Health Information - April 26, 2013 Category: Consumer Health News Source Type: news